In this episode (Recorded in December 2024), Drs. Igor Grant, MD and Jamie Corroon, ND, MPH discuss the potential implications of rescheduling cannabis from a Schedule I to a Schedule III controlled substance. They explore the current scheduling system, the medicinal value of cannabis, the challenges researchers face under Schedule I, and how rescheduling could impact research and funding. They also emphasize the need for harmonization between state and federal laws to facilitate cannabis research.

Takeaways

• Rescheduling cannabis would acknowledge its medicinal value.Research on cannabis is heavily regulated under Schedule One.Moving to Schedule Three would ease some research restrictions.The FDA and DEA play crucial roles in cannabis research approval.More manufacturers of cannabis products for research have been approved recently.The stigma around cannabis research may decrease with rescheduling.Current cannabis products from dispensaries cannot be used in research.Standardization of cannabis products for research is challenging.Harmonization of state and federal laws is essential for effective research.

Chapters

00:00 - Intro

01:08 - Conversation with Dr. Grant

17:29 - Outro